Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer

Gefitinib (‘Iressa’, ZD1839) is an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated antitumour activity and favourable tolerability in Phase II studies. We investigated whether EGFR expression levels could predict for response to gefitinib in pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Parra, H S, Cavina, R, Latteri, F, Zucali, P A, Campagnoli, E, Morenghi, E, Grimaldi, G C, Roncalli, M, Santoro, A
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2004
Assuntos:
Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409824/
https://ncbi.nlm.nih.gov/pubmed/15187994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601923
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados